Positive Regulatory Response Marks Important Milestone for NS002 Development ProgramTEL AVIV, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback